| Name | Title | Contact Details |
|---|
PWNHealth is a national clinician network working to improve early detection and prevention of disease using advanced diagnostics and telehealth. Our model enables safe and easy access to diagnostic testing, ensuring clinical validity, utility, quality consumer education, access to clinicians, and the ability to implement national programs seamlessly. Our solutions provide the clinical, legal, and technological framework to facilitate population-scale testing across key healthcare markets. Through integration with more than 80 CLIA-certified labs and support of over 3,000 test types, we are shaping a new paradigm in healthcare, servicing all 50 states and Puerto Rico. We believe that empowering people with convenient access to clinically actionable testing has the power to change lives, improve outcomes, and create a healthier world. PWNHealth is backed by leading growth equity firms Spectrum Equity and the Blue Venture Fund (BVF).
HealthLynked (OTCQB: HLYK) provides a solution for both patient members and providers to improve healthcare by efficiently exchanging medical information. The HealthLynked Network is a cloud-based platform that allows members to connect with their healthcare providers and take control of their medical data. Members can enter their medications, allergies, past surgeries, and personal health records into one convenient online and secure location. Participating healthcare providers can connect with their current and future patients through the HealthLynked Network. Providers also get the benefit of using HealthLynked marketing tools to communicate with their active and inactive patients to improve patient retention, access accurate patient information, and provide efficient online scheduling.
Gennev is a virtual care provider for women in menopause, offering telehealth doctors, health coaches, products, and education to help women feel 100% again.
SCYNEXIS, Inc. is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. Our scientists have extensive experience in the life sciences industry having, together and individually, been involved in the discovery and development of innovative medicines over a broad range of therapy areas. We are developing our lead product candidate, SCY-078, a novel antifungal in Phase 2, as a novel oral and intravenous drug for the treatment of serious and life-threatening invasive fungal infections in humans.
Stortford Medical is a West Windsor, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.